Octreotide。回顾其药效学和药代动力学性质,和治疗潜在的条件与肽分泌过多有关。
文章的细节
-
引用
复制到剪贴板 -
祁立天SP Battershill PE
Octreotide。回顾其药效学和药代动力学性质,和治疗潜在的条件与肽分泌过多有关。
药。1989年11月,38 (5):658 - 702。doi: 10.2165 / 00003495-198938050-00002。
- PubMed ID
-
2689136 (在PubMed]
- 文摘
-
Octreotide是生长激素抑制素的类似物。像内源性生长激素抑制素,它产生一种强有力的抑制作用于垂体前叶生长激素的释放和促甲状腺激素和肽的gastroenteropancreatic内分泌系统,而克服的一些缺点体内注射生长激素抑制素,即行动的时间短,需要静脉管理和postinfusion反弹分泌过多的激素。临床研究表明,octreotide是有效的治疗肢端肥大症和thyrotrophinomas。比较试验octreotide明显优于溴麦角环肽在肢端肥大症患者。Octreotide似乎也提供一个显著优于现有的疗法的管理类癌综合征和提供了相当大的扭转良性肿瘤的治疗潜力危机可能危及生命。肿瘤患者的试验生产——血管活性肠肽表明octreotide这个条件可能是一个有效的一线选择,通常已扩散至,成为耐火材料传统的症状治疗。在有限的少数高产分泌性腹泻患者的研究,包括cryptosporidium-related腹泻与艾滋病和小肠动静脉瘘患者,octreotide已被证明是有效地减少粪便/瘘输出。然而,设计良好的临床试验还需要确认这些疾病的长期有效性。同样,尽管使用octreotide nesidioblastosis造成的其他条件,如新生儿低血糖,反应性胰腺炎,胰岛素依赖型糖尿病,餐后低血压和倾倒综合征提供了令人鼓舞的初步结果,需要更多的研究来阐明octreotide的地方在他们的治疗。总的来说,octreotide似乎是耐受性良好最常报道的反应是在注射部位出现的疼痛和胃肠道症状,如腹部绞痛,恶心,腹胀,肠胃气胀、腹泻和脂肪痢。 These adverse effects usually abate with time. Additionally, octreotide, like endogenous somatostatin, may also result in cholelithiasis, presumably by altering fat absorption and possibly by decreasing motility of the gallbladder. Thus, octreotide represents a new departure from traditional therapies in the treatment of various pathophysiological states associated with excessive peptide production and secretion. It offers a significant advantage over existing therapies in the medical management of patients with acromegaly, thyrotrophinomas, the carcinoid syndrome, tumours producing vasoactive intestinal peptide and severe secretory diarrhoea in whom conventional management options have either become exhausted or have provided suboptimal symptomatic relief.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物